In February 2013, peginesatide was pulled from the market (all of the product was recalled) to investigate reports of dangerous allergic reactions, including fatal anaphylactic reactions, which appear to be occurring more frequently than anticipated. This medication will not be available until further notice.
Peginesatide (Omontys®) is a medication approved to treat anemia caused by chronic kidney failure. At this time, there are no known peginesatide drug interactions. It is important to understand that specific studies to check for interactions with peginesatide have not been performed, and it is possible that there are potential reactions that are currently unknown.
Peginesatide should not be combined with epoetin alfa (Epogen®, Procrit®) or darbepoetin alfa (Aranesp®). These medications are quite similar, with a few important differences, and using them together would increase the risk for side effects.
Due to the general lack of information at this time, make sure to check with your healthcare provider and pharmacist before combining peginesatide with other medications, as new information on drug interactions may become available at any time.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Food and Drug Administration, Center for Drug Evaluation and Research. FDA alerts health care providers of recall of anemia drug Omontys (February 24, 2013). FDA Web site. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340899.htm. Accessed March 5, 2013.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click